12月16日 - ** 药物开发商Palvella Therapeutics PVLA.O股价上涨6.14%至94.45美元
** Truist将目标股价从105美元上调至190美元，较上一交易日上涨113.5%。
** Truist称，该公司Qtorin凝胶的小型概念验证研究为皮肤静脉畸形患者提供了充分的 "去风险 "机会，皮肤静脉畸形是一种导致静脉功能障碍的罕见遗传性皮肤病。
** 经纪公司称，研究结果可能低估了治疗效果的峰值，因为12周时治疗效果仍在加深
** 15 家券商中有 15 家将该股评为 "买入 "或 "强力买入"；PT 中位数为 190 美元--数据由 LSEG 编制
** 截至上次收盘，PVLA年累计上涨641.5%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.